Sartorius Aktiengesellschaft/€SRT

06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX

About Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft is a German company engaged in the development, manufacturing, and distribution of laboratory equipment and bioprocess solutions. The company's core business is centered around two main segments: Bioprocess Solutions, which includes products for the production of biopharmaceuticals, such as filters, bags, and bioreactors, and Lab Products & Services, offering laboratory instruments like balances and pipettes for various research applications. Founded in 1870, Sartorius is headquartered in Göttingen, Germany, and maintains a global presence with operations in Europe, Asia, and the Americas. Its strategic positioning is reinforced by a strong focus on innovation and comprehensive product offerings catering to the biopharmaceutical industry. Competitive strengths include robust R&D capabilities and a well-integrated supply chain that supports rapid adaptation to industry demands. Sources: Sartorius Corporate Website, Annual Reports.

Ticker

€SRT
Sector
Health

Primary listing

XETRA

Employees

13,878
Headquarters
Göttingen, Germany
Website
www.sartorius.com

SRT Metrics

BasicAdvanced
€15B
-
-
-
€0.73
0.38%

Bulls say / Bears say

Fourth-quarter orders for the Bioprocess Solutions division rose 23.1% to €856.7 million, beating J.P. Morgan estimates by 22%, while annual underlying EBITDA of €945 million topped consensus of €932.7 million, underscoring robust demand recovery in its core consumables business (Reuters)
Deutsche Bank upgraded Sartorius to “Buy” after Q1 results showed a second consecutive quarter of strong order intake with no tariff-related pull-forward effects, highlighting genuine recovery in consumables that represent 75% of group sales and conservative 2025 guidance (Reuters)
For 2025, management forecasts continuous demand recovery and group sales revenue growth of around 6%—with underlying EBITDA expected to outpace sales growth—reflecting positive volume trends and an improved product mix in its high-margin consumables segment (Reuters)
JPMorgan projects Sartorius’ Q1 2025 underlying EBITDA to come in 3% below consensus for the parent and 4% below for Stedim, with sales growth and margin expansion likely trailing estimates, which pressured shares by around 4% ahead of the results (Reuters)
Sartorius shares fell 4.6% after analysts inferred from management’s comment that the rolling 12-month book-to-bill ratio implied Bioprocess Solutions orders in Q2 dipped below 1, signaling a moderation in order momentum despite first-half revenue growth of 6.1% (Reuters)
In Q1 2025, Sartorius reported a 9.3% drop in revenue to €819.6 million and a 13.8% decline in EBITDA to €234.4 million, triggering an 11.2% plunge in its share price as investors reacted to weakening top-line and profitability metrics (WSJ)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SRT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs